1. Home
  2. ZURA vs CIK Comparison

ZURA vs CIK Comparison

Compare ZURA & CIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZURA
  • CIK
  • Stock Information
  • Founded
  • ZURA 2022
  • CIK 1987
  • Country
  • ZURA United States
  • CIK United States
  • Employees
  • ZURA N/A
  • CIK N/A
  • Industry
  • ZURA Biotechnology: Biological Products (No Diagnostic Substances)
  • CIK Finance/Investors Services
  • Sector
  • ZURA Health Care
  • CIK Finance
  • Exchange
  • ZURA Nasdaq
  • CIK Nasdaq
  • Market Cap
  • ZURA 137.2M
  • CIK 163.1M
  • IPO Year
  • ZURA N/A
  • CIK N/A
  • Fundamental
  • Price
  • ZURA $3.34
  • CIK $2.87
  • Analyst Decision
  • ZURA Buy
  • CIK
  • Analyst Count
  • ZURA 9
  • CIK 0
  • Target Price
  • ZURA $11.00
  • CIK N/A
  • AVG Volume (30 Days)
  • ZURA 4.3M
  • CIK 115.4K
  • Earning Date
  • ZURA 11-06-2025
  • CIK 01-01-0001
  • Dividend Yield
  • ZURA N/A
  • CIK 9.03%
  • EPS Growth
  • ZURA N/A
  • CIK N/A
  • EPS
  • ZURA N/A
  • CIK N/A
  • Revenue
  • ZURA N/A
  • CIK N/A
  • Revenue This Year
  • ZURA N/A
  • CIK N/A
  • Revenue Next Year
  • ZURA N/A
  • CIK N/A
  • P/E Ratio
  • ZURA N/A
  • CIK N/A
  • Revenue Growth
  • ZURA N/A
  • CIK N/A
  • 52 Week Low
  • ZURA $0.97
  • CIK $2.50
  • 52 Week High
  • ZURA $4.96
  • CIK $3.19
  • Technical
  • Relative Strength Index (RSI)
  • ZURA 55.62
  • CIK 35.93
  • Support Level
  • ZURA $3.18
  • CIK $2.82
  • Resistance Level
  • ZURA $3.51
  • CIK $2.99
  • Average True Range (ATR)
  • ZURA 0.36
  • CIK 0.03
  • MACD
  • ZURA -0.08
  • CIK -0.01
  • Stochastic Oscillator
  • ZURA 50.40
  • CIK 26.47

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

About CIK Credit Suisse Asset Management Income Fund Inc.

Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.

Share on Social Networks: